This article is more than 5 years old. Information may no longer be current.
Patients with active uveitis treated with adalimumab achieve better visual acuity
Click Here to Manage Email Alerts
Patients with noninfectious intermediate, posterior or panuveitis treated with adalimumab experienced improved best corrected visual acuity and reduced daily uveitis-related systemic corticosteroid use.
Patients with uveitis were enrolled in VISUAL III, a phase 3, open-label, multicenter clinical trial extension. Patients received Humira (adalimumab, AbbVie) 40 mg every other week, and follow-up was through 78 weeks.
In total, 371 of 424 patients were included in the intent-to-treat analysis. The beginning of the study included 242 patients with active uveitis, and 145 of those patients achieved quiescence at week 78. Additionally, 95 of 143 patients were corticosteroid-free at week 78.
Mean BCVA in left and right eyes improved in patients with active uveitis at study entry to week 78 and remained stable throughout the study in eyes with inactive uveitis.
Mean corticosteroid dose for active uveitis patients at study entry was 13.6 mg per day. It decreased to 2.6 mg per day at week 78. The observed mean corticosteroid dose for inactive uveitis patients was low at study entry and experienced little change through week 78.
“About two-thirds of patients who entered VISUAL III with active uveitis achieved quiescence by week 78 with a substantially reduced uveitis-related corticosteroid dose; additionally, mean BCVA was improved over time in patients with active uveitis,” the study authors wrote. – by Robert Linnehan
Disclosures: Suhler reports he is on the steering committee for AbbVie; is a consultant for AbbVie, Gilead, Inotek, Mallinckrodt, Xoma and Santen; and receives research support from AbbVie, Aldeyra, Bristol-Myers Squibb, EyeGate, Clearside, Genentech and pSivida. Please see the study for all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts